The Global Health Body Issues Concern Over Severe Shortage of Weight-Loss Injections

Under a tenth of individuals that would benefit from obesity jabs like Wegovy can access them, caution the WHO as it issues its first recommendations on the therapies.

Given over a billion people worldwide currently classified as obese, it is urging broader and more equitable access to GLP-1 medication.

According to estimates, more than two billion are projected to be obese by 2030 unless action is taken.

"The new guidelines acknowledges that excess weight is a long-term condition that can be managed with thorough and lifelong treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and logistical bottlenecks are major obstacles to broad availability to the jabs that can help people shift substantial weight, explains the body.

Skinny Jab Scarcity

Even under the current best projected outlook, the production of such drugs might only reach about 100 million people – under 10% of those who need them, as stated by the WHO.

The advice calls on countries and companies to widen access, via approaches like patent sharing.

A patent on semaglutide – the main ingredient of the drug Wegovy – is due to expire in several nations in 2026.

The Way Weight-Loss Drugs Operate

The injections replicate a biological compound to slow digestion, curb appetite and enhance feelings of fullness so people eat less.

People usually begin shedding pounds in the initial weeks of starting on the weekly injections.

Studies indicates patients may see weight return a year later of discontinuing the treatment, when their normal appetite resume.

To be above a healthy weight elevates your risk for experiencing medical conditions, including diabetes, cardiovascular issues, stroke, and specific malignancies.

Excess weight concerns people in every country and was linked to 3.7 million fatalities worldwide in 2024, according to the health agency.